Abstract
Although genetic and non-genetic studies in mouse and human implicate the CD40 pathway in rheumatoid arthritis (RA), there are no approved drugs that inhibit CD40 signaling for clinical care in RA or any other disease. Here, we sought to understand the biological consequences of a CD40 risk variant in RA discovered by a previous genome-wide association study (GWAS) and to perform a high-throughput drug screen for modulators of CD40 signaling based on human genetic findings. First, we fine-map the CD40 risk locus in 7,222 seropositive RA patients and 15,870 controls to identify a single SNP that explains the entire signal of association (rs4810485, P = 1.4 × 10⁻⁹). Second, we demonstrate that subjects homozygous for the RA risk allele have ~33% more CD40 on the surface of primary human CD19+ B lymphocytes than subjects homozygous for the non-risk allele (P = 10⁻⁹). Third, we use retroviral shRNA infection to perturb CD40 levels and observe a direct correlation between CD40 protein and phosphorylation of RelA (p65), a subunit of the NF-κB transcription factor. Finally, we develop a high-throughput NF-κB luciferase reporter assay and conduct an HTS of 1,982 chemical compounds. We identify 2 novel chemical inhibitors not previously implicated in inflammation or CD40-mediated NF-κB signaling. Our study demonstrates proof-of-concept that human genetics can be used to guide the development of phenotype-based, high-throughput small-molecule screens to identify potential novel therapies in complex traits such as RA.
Introduction
While Genome-Wide Association Studies (GWAS) have identified hundreds of genetic loci associated with complex diseases like Rheumatoid Arthritis (RA), translating these statistical "hits" into clinical therapies remains a significant challenge. Most risk-associated Single Nucleotide Polymorphisms (SNPs) reside in non-coding regions, making it difficult to determine which gene they affect or the direction of their functional impact (gain-of-function vs. loss-of-function). This uncertainty hinders drug development, as researchers do not know whether to activate or inhibit a pathway.
The CD40 pathway is a prime example. Previous attempts to target it using antibodies against the CD40 ligand (CD40L) failed in clinical trials due to severe thromboembolic side effects. This study leverages human genetics to "de-risk" the CD40 pathway and guide the discovery of safer, intracellular small-molecule inhibitors.
Genetic Fine-mapping and Functional Impact
The researchers performed dense genotyping and deep sequencing to pinpoint the causal variant at the CD40 locus. They identified rs4810485 as the primary variant explaining the RA association.
Functional genomics revealed that the RA risk allele (G) acts as a gain-of-function mutation. Carriers of the risk allele exhibit significantly higher levels of CD40 mRNA and protein. Specifically, subjects homozygous for the risk allele (GG) have approximately 33% more CD40 protein on the surface of their B-cells compared to those with the non-risk allele (TT).
This genetic evidence provides a clear therapeutic mandate: because the risk is associated with increased expression, the goal should be to inhibit the pathway. Furthermore, human genetics serves as a natural dose-response curve; since individuals with lower CD40 signaling (heterozygotes for rare loss-of-function mutations) are generally healthy, pharmacological inhibition is likely to be well-tolerated.
High-Throughput Drug Screening
Using the insight that CD40 levels correlate with NF-κB activation (specifically p65 phosphorylation), the authors developed a cell-based reporter system. They engineered a human B-lymphocyte cell line (BL2) with an NF-κB luciferase reporter to screen 1,982 compounds, including FDA-approved drugs.
The screen identified 81 initial hits. After rigorous counter-screening against other pathways (like TNF-alpha and TLR4) and toxicity tests, they identified two novel inhibitors: CID 306804 and CID 7309015. These compounds significantly reduced CD40-mediated B-cell activation in primary human cells from healthy donors.
Conclusion and Future Directions
This study demonstrates a successful "bench-to-bedside" framework. By identifying the direction of effect for a GWAS hit, the researchers were able to design a targeted screening pipeline. Targeting intracellular signaling rather than extracellular binding may bypass the safety issues seen with previous CD40-targeted therapies.
However, limitations remain. The pilot screen used a relatively small library, and the identified compounds appear to be general NF-κB inhibitors rather than CD40-specific. Future work will focus on larger-scale screens to find molecules targeting CD40-specific adapter proteins (like TRAFs) and validating these findings in animal models of arthritis.
Summary updated